Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial

In this open-label study (n=369), median overall survival was similar for patients treated with nivolumab (9.8 months; 95% CI 8.2-11.8) and those treated with bevacizumab (control group; 10.0 months; 95% CI 9.0-11.8).


JAMA Oncology